1686 / 1835
The addition of thiotepa and rituximab to MTX-
ARAC (MATRIX) is associated with significantly
improved CRR and ORR.
A (n= 75)
B (n= 69)
C (n= 75)
p
CR
17 (23%)
(95%CI= 14-31%)
21 (30%)
(95%CI= 21-42%)
37 (49%)
(95%CI= 38-60%)
A vs. B= 0.29
A vs. C= 0.0007
B vs. C= 0.02
PR
23 (31%)
30 (43%)
28 (37%)
OR
40 (53%)
(95%CI= 42-64%)
51 (74%)
(95%CI= 64-84%)
65 (87%)
(95%CI= 80-94%)
A vs. B= 0.01
A vs. C= 0.00001
B vs. C= 0.05
SD
6 ( 8%)
4 ( 6%)
1 ( 1%)
PD
22 (29%)
11 (16%)
6 ( 8%)
TD
7 ( 9%)
3 ( 4%)
3 ( 4%)